LEO Pharma repurchased the US product rights to psoriasis treatments, Talconex®, Talconex Scalp® and Dovonex®, and the dermatology pipeline from Warner Chilcott for nearly US$1 B. Having already acquired Peplin, the deal sets up LEO nicely to conquer the US dermatology market.